New hope for kids with hepatitis c: drug combo trial launches in cambodia
NCT ID NCT05992077
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of two antiviral drugs, sofosbuvir and daclatasvir, in children aged 6 and older with active hepatitis C in Cambodia. The goal is to see if the treatment can clear the virus from the blood 12 weeks after finishing the 12-week course. The trial will enroll up to 21,000 participants and also monitor liver health over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sofosbuvir/daclatasvir (antiviral drugs)
- What this could lead to
- If successful, this could provide a safe and effective treatment to cure hepatitis C in children and adolescents, reducing liver damage and spread of the virus.
- What could go wrong
- This is a pilot study, so results are preliminary. The drugs may not work as well in children, and side effects or relapse are possible. The trial is also limited to Cambodia, so findings may not apply everywhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Battambang Provincial Hospital
Battambang, Cambodia
-
Jayavarman VII Hospital
Siem Reap, Cambodia
-
Kantha Bopha Hospital
Phnom Penh, Cambodia
-
National Pediatric Hospital
Phnom Penh, Cambodia
More trials for these conditions
Other studies related to the condition(s) this trial covers.